Clinical Trials: Investigator Site-Level Audit Findings

Most Frequent Investigator Site Audit Findings in Clinical Trials

Posted on digi By digi

Investigator sites form the foundation of clinical trials. Regardless of sponsor oversight or CRO involvement, the quality of trial conduct at each site determines the overall credibility of a study. Regulatory authorities such as the FDA, EMA, MHRA, and PMDA conduct inspections at investigator sites to verify compliance with ICH-GCP and regional regulations. Site-level audit findings are among the most frequently reported deficiencies in inspection reports, and they can lead to delays, sanctions, or rejection of trial data.

Click to read the full article.

Investigator Site-Level Audit Findings, Regulatory Audit Findings

Missing or Incomplete Informed Consent Forms: A Top Audit Finding

Posted on digi By digi

Informed consent is the ethical and regulatory cornerstone of clinical trial conduct. It ensures that participants are fully aware of the trial’s purpose, procedures, potential risks, and their right to withdraw at any time. Regulatory authorities such as the FDA, EMA, MHRA, and PMDA consistently rank missing or incomplete informed consent documentation among the top audit findings during site inspections.

Click to read the full article.

Investigator Site-Level Audit Findings, Regulatory Audit Findings

Investigator Oversight Deficiencies in Clinical Trial Audit Reports

Posted on digi By digi

Principal Investigators (PIs) hold ultimate responsibility for the conduct of clinical trials at their sites. Regulatory agencies such as the FDA, EMA, and MHRA consistently identify inadequate investigator oversight as a major deficiency during audits and inspections. Oversight failures may include insufficient supervision of delegated tasks, lack of review of source data, or inadequate monitoring of patient safety. These deficiencies undermine compliance with ICH GCP E6(R2), jeopardize data integrity, and potentially expose trial participants to risk.

Click to read the full article.

Investigator Site-Level Audit Findings, Regulatory Audit Findings

Delegation of Authority Log Errors: Why They Appear in Audit Findings

Posted on digi By digi

In clinical trials, the Delegation of Authority (DOA) log is a critical document that records which site staff are authorized to perform specific trial-related tasks under the supervision of the Principal Investigator (PI). Regulatory authorities such as the FDA, EMA, and MHRA often cite errors or gaps in DOA logs as frequent audit findings. These errors are not just clerical; they represent potential breaches of ICH GCP E6(R2) compliance, threatening both data integrity and patient safety.

Click to read the full article.

Investigator Site-Level Audit Findings, Regulatory Audit Findings

Training Record Gaps: Common Site Audit Observations

Posted on digi By digi

In clinical trials, staff training is not optional but a fundamental requirement to ensure protocol compliance, subject safety, and data integrity. One of the most frequent site-level audit findings involves training record gaps. Regulators such as the FDA, EMA, and MHRA consistently cite missing or incomplete training documentation during inspections. These deficiencies highlight a lack of assurance that site personnel are adequately qualified to perform delegated tasks.

Click to read the full article.

Investigator Site-Level Audit Findings, Regulatory Audit Findings

Audit Findings on Adverse Event Reporting Delays at Investigator Sites

Posted on digi By digi

Adverse event (AE) and serious adverse event (SAE) reporting is a cornerstone of subject safety in clinical trials. Regulators, including the FDA, EMA, and MHRA, consider delayed or incomplete reporting of safety events one of the most serious audit findings at investigator sites. These delays not only compromise regulatory compliance but also pose direct risks to patient safety, data reliability, and trial credibility.

Click to read the full article.

Investigator Site-Level Audit Findings, Regulatory Audit Findings

Documentation Gaps in Concomitant Medications: Regulatory Audit Insights

Posted on digi By digi

Concomitant medications—defined as any drug or therapy taken by a subject in addition to the investigational product—play a crucial role in clinical trial safety assessments. Regulatory authorities require complete and accurate documentation of these medications because they can confound efficacy results, contribute to adverse events (AEs), or highlight prohibited drug interactions. Yet, documentation gaps in concomitant medication records remain one of the most common investigator site-level audit findings.

Click to read the full article.

Investigator Site-Level Audit Findings, Regulatory Audit Findings

Protocol Deviations Noted in Site Audits: How to Prevent Them

Posted on digi By digi

Protocol deviations occur when trial conduct does not strictly follow the approved clinical trial protocol. Regulators, including the FDA, EMA, and MHRA, view deviations as a serious threat to both data integrity and patient safety. Even minor deviations, if recurring, can raise questions about the reliability of study outcomes and the adequacy of investigator oversight. As such, protocol deviations consistently appear in regulatory inspection reports and are among the most frequent findings at investigator sites.

Click to read the full article.

Investigator Site-Level Audit Findings, Regulatory Audit Findings

Source Data Verification Failures Leading to Regulatory Findings

Posted on digi By digi

Source Data Verification (SDV) is the process by which clinical monitors confirm that data entered into Case Report Forms (CRFs) or electronic data capture (EDC) systems accurately reflects original source documents, such as patient charts, laboratory reports, or diagnostic test results. SDV is a cornerstone of ICH GCP compliance because it ensures data integrity, reliability, and traceability. Failures in this area are considered high-risk audit findings since they undermine confidence in the trial results and pose potential patient safety concerns.

Click to read the full article.

Investigator Site-Level Audit Findings, Regulatory Audit Findings

Patient Confidentiality Breaches Highlighted in Clinical Site Audits

Posted on digi By digi

Protecting patient confidentiality is one of the core ethical and regulatory requirements in clinical research. Clinical trial subjects volunteer their personal health information (PHI) with the expectation that their identities will remain private, as outlined in international guidance such as ICH GCP E6(R2), the U.S. Health Insurance Portability and Accountability Act (HIPAA), and the EU General Data Protection Regulation (GDPR). When confidentiality safeguards fail, it not only jeopardizes subject trust but also leads to major or critical audit findings during regulatory inspections.

Click to read the full article.

Investigator Site-Level Audit Findings, Regulatory Audit Findings